›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:AmoyDx® HRD Complete Panel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amoy DiagnosticsType:
Laboratory Developed Test
Related tests:
AmoyDx® HRD Complete Panel offers a comprehensive homologous recombination deficiency (HRD) test designed to simultaneously detect genetic abberations across 20 HRR genes and HRD status.
Cancer:
Breast Cancer, Ovarian Cancer, Prostate Cancer
Gene:
ATM (ATM serine/threonine kinase), BARD1 (BRCA1 Associated RING Domain 1), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CDH1 (Cadherin 1)
See More ...
ATM (ATM serine/threonine kinase), BARD1 (BRCA1 Associated RING Domain 1), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CDH1 (Cadherin 1), CDK1 (Cyclin-dependent kinase 1), CHEK1 (Checkpoint kinase 1), CHEK2 (Checkpoint kinase 2), FANCA (FA Complementation Group A), FANCL (FA Complementation Group L), HDAC2 (Histone deacetylase 2), HRD (Homologous Recombination Deficiency), PALB2 (Partner and localizer of BRCA2), PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha), PTEN (Phosphatase and tensin homolog), RAD51B (RAD51 Paralog B), RAD51C (RAD51 paralog C), RAD51D (RAD51 paralog D), RAD54L (DNA Repair And Recombination Protein RAD54), TP53 (Tumor protein P53)
Method:
Next-Generation Sequencing (NGS)
